ADC Therapeutics SA (NYSE:ADCT) Receives $7.50 Average PT from Analysts

ADC Therapeutics SA (NYSE:ADCT) has received an average recommendation of “Moderate Buy” from the six analysts that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $7.50.

A number of research analysts have recently issued reports on ADCT shares. Wall Street Zen upgraded ADC Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $5.00 target price on shares of ADC Therapeutics in a research note on Wednesday, December 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of ADC Therapeutics in a research report on Wednesday, January 21st. Finally, Guggenheim reaffirmed a “buy” rating and issued a $10.00 price objective on shares of ADC Therapeutics in a research report on Wednesday, November 12th.

ADC Therapeutics Stock Performance

NYSE ADCT opened at $4.01 on Friday. The company has a market cap of $496.14 million, a PE ratio of -2.76 and a beta of 1.93. The firm’s 50 day moving average price is $3.73 and its 200-day moving average price is $3.71. ADC Therapeutics has a 52-week low of $1.05 and a 52-week high of $4.80.

Institutional Trading of ADC Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. R Squared Ltd acquired a new position in shares of ADC Therapeutics in the third quarter valued at about $59,000. ProShare Advisors LLC boosted its position in ADC Therapeutics by 27.0% in the fourth quarter. ProShare Advisors LLC now owns 15,727 shares of the company’s stock valued at $56,000 after buying an additional 3,339 shares during the last quarter. AXQ Capital LP acquired a new position in ADC Therapeutics in the 4th quarter worth approximately $57,000. Henrickson Nauta Wealth Advisors Inc. purchased a new position in ADC Therapeutics during the 4th quarter worth approximately $69,000. Finally, SG Americas Securities LLC acquired a new stake in ADC Therapeutics during the 4th quarter valued at approximately $86,000. Hedge funds and other institutional investors own 41.10% of the company’s stock.

About ADC Therapeutics

ADC Therapeutics SA is a clinical-stage biopharmaceutical company focused on the discovery and development of highly targeted antibody-drug conjugates (ADCs) designed to treat hematological malignancies such as non-Hodgkin lymphoma and acute myeloid leukemia. By marrying the specificity of monoclonal antibodies with potent cytotoxic payloads, the company aims to maximize tumor cell eradication while limiting off-target toxicity.

At the core of ADC Therapeutics’ portfolio is loncastuximab tesirine-lpyl, a CD19-directed ADC that received accelerated approval from the U.S.